NeurologyLive® Mind Moments®

NeurologyLive
  • 4.6 (10)
  • Medicine
  • Updated Semimonthly

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com.

  1. 3d ago

    Evaluating New MS Diagnostic Criteria in Atypical Presentations

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Daniel Ontaneda, MD, PhD, professor of neurology at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses a recently published study in Neurology evaluating the application of the 2024 McDonald Criteria in individuals with nonspecific neurologic symptoms or incidental MRI findings. Using data from the CAHPS-MS study, Ontaneda explains how the revised diagnostic criteria perform in these previously understudied patient populations and what the findings may mean for earlier identification of multiple sclerosis.  The conversation explores the rationale behind expanding the 2024 McDonald Criteria, the role of central vein sign and cerebrospinal fluid oligoclonal bands in improving diagnostic confidence, and how clinicians should approach patients who fall into a diagnostic gray zone. Ontaneda also discusses the practical application of the updated criteria, the importance of longitudinal follow-up, and how emerging biomarkers may continue to refine MS diagnosis in the years ahead.   Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page. Episode Breakdown: 1:15 – Why the 2024 McDonald Criteria expanded diagnostic eligibility 4:30 – Applying the criteria in nonspecific symptom presentations 6:20 – Clinical relevance of symptom patterns and MRI findings 8:40 – Using biomarkers to improve diagnostic confidence 11:25 – Neurology News Minute  13:55– Interpreting dissemination in time with updated criteria 15:45 – Future validation of emerging MS diagnostic biomarkers The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Advisory Committee Schedules Meeting to Review Deramiocel's BLA in Duchenne Muscular Dystrophy FDA Clears PoNS Device for Stroke Rehabilitation, Expanding Neurostimulation Beyond MS Indication FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    17 min

  2. Jun 26

    A Clinical Guide to Diagnosing and Managing ADEM

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Grace Gombolay, MD, associate professor of pediatrics at Emory University School of Medicine and director of the Pediatric Neuroimmunology and Multiple Sclerosis Program at Children's Healthcare of Atlanta, joins Varun Kannan, MD, assistant professor of pediatrics in the Department of Neurology at Emory University School of Medicine and Children's Healthcare of Atlanta, for a discussion on acute disseminated encephalomyelitis (ADEM), a rare inflammatory demyelinating syndrome that remains an important diagnostic consideration in pediatric neuroimmunology. The conversation provides a practical overview of how clinicians should recognize ADEM, distinguish it from conditions such as multiple sclerosis, MOG antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), and approach treatment in the absence of FDA-approved therapies.  Gombolay and Kannan review the clinical and radiographic hallmarks of ADEM, the role of MRI and antibody testing in the diagnostic workup, and current treatment strategies involving corticosteroids, IVIG, and plasma exchange. They also discuss long-term outcomes, the evolving relationship between ADEM and MOGAD, emerging biomarkers such as neurofilament light chain and cytokine profiling, and common misconceptions that can complicate diagnosis and management in clinical practice.  Looking for more Multiple sclerosis & demyelinating disorders discussion? Check out the NeurologyLive® Multiple sclerosis & demyelinating disorders clinical focus page. Episode Breakdown: 1:15 – Recognizing the clinical and imaging features of ADEM 3:30 – Distinguishing ADEM from MS, MOGAD, and NMOSD 7:20 – Current treatment approaches and management strategies 10:10 – Neurology News Network  12:40 – Long-term outcomes and monitoring after recovery 15:55 – Emerging biomarkers and improving diagnostic precision 19:10 – Preventing future attacks and reducing relapse risk 21:10 – Remaining research gaps and unanswered questions in ADEM The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    27 min

  3. Jun 12

    Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory.  The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development.  Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page. Episode Breakdown: 1:10 – PROCEED trial efficacy in patients with prior preventive failures 5:10 – Safety and tolerability findings for bocunebart 6:30 – Coadministration data with ubrogepant and clinical implications 8:30 – Neurology News Network  10:50 – Rationale for combining PACAP and CGRP-targeted therapies 13:40 – Key considerations for future phase 3 development The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    18 min

  4. May 29

    New AASM Guidance on Combination Treatment for Chronic Insomnia

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice.  The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care.  Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page. Episode Breakdown: 1:15 – Why formal insomnia combination treatment guidance was needed 2:45 – Defining concurrent CBT-I and pharmacotherapy approaches 4:35 – Evidence supporting CBT-I as foundational insomnia treatment   7:15 – Situations where combination therapy may improve patient outcomes 7:50 – Neurology News Network  10:20 – Patient-specific factors influencing insomnia treatment selection 12:30 – Barriers involving CBT-I access, cost, and real-world implementation 16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    20 min

  5. May 15

    Understanding RNFL Asymmetry as a Biomarker in Pediatric MS

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets.  Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page. Episode Breakdown: 1:15 – Optic nerve involvement and updated MS diagnostic criteria  3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings 5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS  6:40 – Neurology News Network  8:40 – Feasibility of incorporating OCT into neurology and MS practice  10:15 – Future research directions, including normative data and visible light OCT The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    15 min

  6. May 1

    Addressing Cognitive Decline in Parkinson Disease

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Greg Pontone, MD, Chief of Aging Behavioral and Cognitive Neurology at the University of Florida, joins the podcast to discuss the interplay between cognition and Parkinson disease, with a focus on how clinicians can better recognize and manage cognitive changes across the disease course. Pontone outlines the prevalence of early cognitive impairment, noting that a significant proportion of patients may present with subtle deficits at diagnosis, particularly in executive function and processing speed.  The conversation explores the impact of commonly used medications on cognition, including anticholinergics and benzodiazepines, and how clinicians can balance therapeutic benefit with cognitive risk. Pontone also reviews current treatment strategies, including cholinesterase inhibitors and memantine, while emphasizing the importance of nonpharmacologic approaches such as structured routines and cognitive training. Additional discussion highlights the evolving role of biomarkers, the overlap between Parkinson disease and Alzheimer pathology, and the need for earlier recognition, better patient education, and continued research to improve long-term cognitive outcomes in this population. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:10 – Prevalence and early signs of cognitive impairment in Parkinson disease  2:30 – Medication-related cognitive effects and contributing drug classes 4:20 – Balancing therapeutic benefit vs cognitive risk in treatment decisions 6:05 – Current treatments for cognition, including pharmacologic and behavioral strategies 10:25 – Neurology News Network  13:00 – Role of biomarkers and Alzheimer overlap in Parkinson cognition 15:45 – Future priorities for advancing cognitive care and research in PD The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    20 min

  7. Apr 17

    Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Julie Kurek, MD, Associate Professor of Neurology at Augusta University/Wellstar-MCG, joins the podcast to provide a clinical breakdown of how neurologists can differentiate dyskinesia from tremor in patients with Parkinson disease and other movement disorders. Drawing from bedside experience, Kurek outlines the key phenomenologic differences between these movements, emphasizing the importance of rhythm, distribution, and overall movement quality in distinguishing the two.  The conversation also explores how timing in relation to levodopa dosing serves as a critical diagnostic anchor, including recognition of peak-dose and biphasic dyskinesias. Kurek discusses real-world challenges in identifying patient-specific patterns, the importance of clinician–patient communication, and common diagnostic pitfalls, particularly in younger-onset or atypical presentations. She also highlights the growing role of digital tools, including wearable sensors and adaptive deep brain stimulation, in improving longitudinal monitoring and refining diagnostic accuracy in movement disorders. Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page. Episode Breakdown: 1:10 – Clinical features distinguishing tremor vs dyskinesia at bedside  3:50 – Role of medication timing and levodopa response patterns 9:00 – Identifying patient-specific patterns and symptom awareness challenges  13:20 – Neurology News Network  16:10 – Common diagnostic pitfalls in Parkinson disease and movement disorders 17:50 – Role of wearables, biomarkers, and adaptive DBS in differentiation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts Ultragenyx's Resubmitted BLA for MPS IIIA Gene Therapy UX111 Elecsys NfL Test Receives European Approval for Monitoring Neuroinflammation in Relapsing-Remitting Multiple Sclerosis FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    25 min

  8. Apr 3

    The Clinical Reality of Seronegative Myasthenia Gravis

    Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment. Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:15 – Defining seronegative MG and estimating prevalence within overall patient population  2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders  5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response  6:50 – Neurology News Network  9:05 – Current treatment strategies and variability in access to targeted therapies  11:55 – Barriers to clinical trials and need for improved patient stratification methods  13:05 – Key unanswered questions including biomarkers and reassessing diagnosis in nonresponders  The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts Zilganersen New Drug Application for Priority Review in Alexander Disease FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

    17 min
See All (191)

Ratings & Reviews

4.6
out of 5
10 Ratings

About

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com.

Information

You Might Also Like